DPP4 and metabolic dysfunction-associated steatotic liver disease: In addition, incretin-related drugs, such as glucagon-like peptide-1 (GLP-1) receptor analogue and dipeptidyl peptidase-4 (DPP-4) inhibitor, improve liver function, glucose metabolism and histological findings in NAFLD patients with T2DM [15,160,161,162,163,164,165].